Supporting Information

To accompany

Clicked cinnamic/caffeic esters and amides as radical scavengers and 5-lipoxygenase inhibitors.

Jérémie A. Doiron^a, Benoît Métayer^a, Ryan R. Richard^a, Dany Desjardins^a, Luc H. Boudreau^{a,b}, Nathalie A. Levesque^a, Jacques Jean-François^a, Samuel J. Poirier^a, Marc E. Surette^a, Mohamed Touaibia^a*.

^a Département de chimie et biochimie, Université de Moncton, Moncton, NB, Canada

^b Centre de Recherche en Rhumatologie et Immunologie et Faculté de Médecine, Université Laval, Québec, Canada QC

*Author to whom correspondence should be addressed;

E-Mail: mohamed.touaibia@umoncton.ca;

Tel.: +1-506-858-4493; Fax: +1-506-858-4541.

Chemistry

All chemicals used were purchased from Aldrich (CA) and used without further purification. Purification of compounds was carried out by silica gel circular chromatography (Chromatotron®, model 7924, Harrison Research) or by flash chromatography. TLC was run on silica gel coated aluminium sheets (SiliaPlate TLC, Silicycle®) with detection by UV light (254 nm, UVS-11, Mineralight® shortwave UV lamp). Melting points were obtained using a MELTEMP® (model 1001D) melting point apparatus. FTIR spectra were recorded on a Nicolet® Impact 400 spectrometer. NMR spectra were recorded on a Bruker® Avance III 400 MHz spectrometer using TMS as an internal standard. High-resolution mass measurements were performed on a Bruker® Doltonics' micrOTOF instrument in positive or negative electrospray.

General procedure I - Monosubstituted triazoles from organic azides and acetylene

To a vigorously stirred solution of the appropriate organic azide (1 mmol, 1 eq.) in 6 mL DMSO is added copper (I) iodide (0.1 mmol, 0.1 eq), after which the reaction vessel is thoroughly flushed with acetylene gas and sealed under balloon pressure. Triethylamine (1.2 mmol, 1.2 eq.) is then added and the mixture is left to react overnight at room temperature. The resulting solution is partitioned between 125 mL of brine and 25 mL ethyl acetate, after which the aqueous phase is extracted three more times with 25 mL ethyl acetate. The organic phase is then washed twice with brine, treated with charcoal, dried over MgSO₄ and concentrated. The resulting oil is purified by silica gel circular chromatography (Chromatotron[®] model 7924, Harrison Research, eluent: MeOH/CH₂Cl₂).

General procedure IIA - Anhydrous CuAAC reaction

To a vigorously stirred solution of the appropriate organic azide (0.5 mmol, 1 eq.) and alkyne (0.75 mmol, 1.5 eq.) in 4 mL THF, is added copper (I) iodide (0.025 mmol, 0.05 eq) followed by triethylamine (0.6 mmol, 1.2 eq). The reaction mixture is stirred overnight under argon atmosphere. The resulting solution is partitioned between 30 mL AcOEt and 30 mL H₂O, after

which the aqueous phase is extracted twice more with 30 mL AcOEt. The combined organic fractions are washed twice with saturated ammonium chloride (20 mL), twice with brine, dried over MgSO₄ and concentrated. The resulting oil is purified by silica gel circular chromatography (Chromatotron[®] model 7924, Harrison Research, eluent: AcOEt/Hex or MeOH/CH₂Cl₂).

General procedure IIB - Aqueous CuAAC reaction

To a vigorously stirred solution of the appropriate organic azide (0.5 mmol, 1 eq.) and alkyne (0.75 mmol, 1.5 eq.) in 2.5 mL THF is added CuSO₄·5H₂O (0.05 mmol, 0.1 eq) dissolved in 2.5 mL H₂O followed by sodium ascorbate (0.05 mmol, 0.1 eq), after which the mixture is left to react overnight. The resulting solution is then diluted to 30 mL with water and extracted three times with AcOEt (20 mL). The organic fractions are then combined, washed twice with water, twice with saturated ammonium chloride, twice with brine, dried over MgSO₄ and concentrated. The resulting oil is purified by silica gel circular chromatography (Chromatotron® model 7924, Harrison Research, eluent: AcOEt/Hex or MeOH/CH₂Cl₂).

General procedure III – Deacetylation of diacetylcaffeoyl derivatives

The appropriate diacetylcaffeoyl derivative (0.25 mmol, 1 eq) is dissolved in 2 mL anhydrous CH₂Cl₂ under N₂, to which is added 4 mL MeOH. To the resulting stirred solution is added guanidinium hydrochloride (0.81 mmol, 3.25 eq.) followed by triethylamine (2.44 mmol, 9.75 eq). After consumption of the diacetylated precursor (about 2h), the reaction mixture is concentrated and partitioned between 60 mL AcOEt and 30 mL water. The organic phase is then washed again with water, twice with saturated ammonium chloride, twice with brine, treated with charcoal, dried over MgSO₄ and concentrated to give the resulting pure caffeoyl derivative as fine powders.

2-(4-Cyclohexyl-1H-1,2,3-triazol-1-yl)ethyl cinnamate (8c)

Following general procedure IIA with azide **6** and ethynylcyclohexane, compound **8c** was obtained as a white solid after silica gel circular chromatography (0 - 25% AcOEt/Hex), yield = 38%. Mp = 119 °C, R_f = 0.37 (50% AcOEt/Hex). ¹H NMR (400 MHz, CDCl₃, 25 °C), δ (ppm) = 7.71 (d, 1H, J = 16.0 Hz, =CHC_{ar}), 7.56 – 7.54 (m, 2H, H_{ar}), 7.43 – 7.40 (m, 3H, H_{ar}), 7.35 (s, 1 H, =CHN), 6.44 (d, 1H, J = 16.0 Hz, =CHCO), 4.68 (t, 2H, J = 5.1 Hz, OCH₂), 4.62 (t, 2H, J = 5.1 Hz, CH₂N), 2.81 – 2.77 (m, 1H, CH-triazole), 2.09 – 2.04 (m, 2H, cyclohexyl), 1.86 – 1.80 (m, 2H, cyclohexyl), 1.49 – 1.36 (m, 4H, cyclohexyl), 1.31 – 1.25 (m, 2H, cyclohexyl); ¹³C NMR (101 MHz, CDCl₃, 25 °C), δ (ppm) = 166.3, 154.0, 146.0, 134.0, 130.7, 129.0, 128.2, 119.9, 116.9, 62.6, 49.0, 35.3, 33.0, 26.1, 26.0. HRMS m/z calc. for $C_{19}H_{23}N_3O_2 + H^+$: 326.1863; detected: 326.1860.

2-(4-(Cyclohex-1-en-1-yl)-1H-1,2,3-triazol-1-yl)ethyl cinnamate (**8d**)

Following general procedure IIA with azide **6** and 1-ethynylcyclohex-1-ene, compound **8d** was obtained as a white solid after silica gel circular chromatography (0 - 30% AcOEt/Hex), yield = 79%. Mp = 101 - 103 °C, $R_f = 0.51$ (50% AcOEt/Hex). ¹H NMR (400 MHz, CDCl₃, 25 °C), δ (ppm) = 7.71 (d, 1H, J = 16.0 Hz, =CHC_{ar}), 7.56 – 7.53 (m, 2H, H_{ar}), 7.50 (s, 1H, =CHN), 7.43 – 7.39 (m, 3H, H_{ar}), 6.56 – 6.54 (m, 1 H, CH=C-triazole), 6.43 (d, 1H, J = 16.0 Hz, =CHCO), 4.70 (t, 2H, J = 5.2 Hz, OCH₂), 4.62 (t, 2H, J = 5.2 Hz, CH₂N), 2.42 – 2.40 (m, 2H, cyclohexenyl), 2.25 – 2.21 (m, 2H, cyclohexenyl), 1.82 – 1.76 (m, 2H, cyclohexenyl), 1.72 – 1.65 (m, 2H, cyclohexenyl); ¹³C NMR (101 MHz, CDCl₃, 25 °C), δ (ppm) = 166.4, 149.8, 146.1, 134.0, 130.7, 129.0, 128.3, 127.2, 125.3, 118.8, 116.9, 62.6, 49.1, 26.4, 25.3, 22.5, 22.2. HRMS m/z calc. for C₁₉H₂₁N₃O₂ + H⁺: 324.1707; detected: 324.1707.

2-(4-Phenyl-1H-1,2,3-triazol-1-yl)ethyl cinnamate (8e)

Following general procedure IIA with azide **6** and ethynylbenzene, compound **8e** was obtained as a white solid after silica gel circular chromatography (0 - 25% AcOEt/Hex), yield = 67%. Mp = 122 - 123 °C, $R_f = 0.40$ (50% AcOEt/Hex). ¹H NMR (400 MHz, CDCl₃, 25 °C), δ (ppm) =

7.88 - 7.86 (m, 3H, H_{ar} + =CHN), 7.73 (d, 1H, J = 16.0 Hz, =CHC_{ar}), 7.55 - 7.53 (m, 2H, H_{ar}), 7.47 - 7.35 (m, 6H, H_{ar}), 6.45 (d, 1H, J = 16.0 Hz, =CHCO), 4.78 (t, 2H, J = 5.1 Hz, OCH₂), 4.69 (t, 2H, J = 5.1 Hz, CH₂N); 13 C NMR (101 MHz, CDCl₃, 25 °C), δ (ppm) = 166.4, 148.1, 146.3, 134.0, 130.7, 130.5, 129.0, 128.9, 128.3, 125.8, 120.2, 116.8, 62.5, 49.3. HRMS m/z calc. for $C_{19}H_{17}N_3O_2 + H^+$: 320.1394; detected: 320.1319.

2-(4-(p-Tolyl)-1H-1,2,3-triazol-1-yl)ethyl cinnamate (**8f**)

Following general procedure IIA with azide **6** and 1-ethynyl-4-methylbenzene, compound **8f** was obtained as a white solid after silica gel circular chromatography (0 - 25% AcOEt/Hex), yield = 67%. Mp = 139 - 140 °C, $R_f = 0.67$ (60% AcOEt/Hex). ¹H NMR (400 MHz, CDCl₃, 25 °C), δ (ppm) = 7,83 (s, 1H, =CHN), 7.76 - 7.70 (m, 3 H, H_{ar} + =CHC_{ar}), 7.55 - 7.53 (m, 2H, H_{ar}), 7.42 - 7.41 (m, 3H, H_{ar}), 7.26 (d, 2H, J = 7.9 Hz, H_{ar}), 6.45 (d, 1H, J = 16.0 Hz, =CHCO), 4.76 (t, 2H, J = 4.9 Hz, OCH₂), 4.68 (t, 2H, J = 4.9 Hz, CH₂N), 2.40 (s, 3H, CH₃); ¹³C NMR (101 MHz, CDCl₃, 25 °C), δ (ppm) = 166.4, 148.2, 146.2, 138.1, 134.0, 130.7, 129.6, 129.0, 128.3, 127.6, 125.7, 119.8, 116.8, 62.6, 49.3, 21.3. HRMS m/z calc. for $C_{20}H_{19}N_3O_2 + H^+$: 334.1550; detected: 334.1549.

2-(4-(4-Fluorophenyl)-1H-1,2,3-triazol-1-yl)ethyl cinnamate (8g)

Following general procedure IIA with azide **6** and 1-ethynyl-4-fluorobenzene, compound **8g** was obtained as a white solid after silica gel circular chromatography (0 - 25% AcOEt/Hex), yield = 83%. Mp = 134 - 135 °C, $R_f = 0.51$ (50% AcOEt/Hex). ¹H NMR (400 MHz, CDCl₃, 25 °C), δ (ppm) = 7.85 - 7.81 (m, 3H, H_{ar} + =CHN), 7.73 (d, 1H, J = 16.0 Hz, =CHC_{ar}), 7.54 - 7.52 (m, 2H, H_{ar}), 7.42 - 7.41 (m, 3H, H_{ar}), 7.14 (t, 2H, J = 8.7 Hz, H_{ar}), 6.45 (d, 1H, J = 16.0 Hz, =CHCO), 4.77 (t, 2H, J = 5.0 Hz, OCH₂), 4.69 (t, 2H, J = 5.0 Hz, CH₂N); ¹³C NMR (101 MHz, CDCl₃, 25 °C), δ (ppm) = 166.4, 164.0, 161.5, 147.3, 146.3, 134.0, 130.8, 129.0, 128.3, 127.6, 127.5, 126.7, 126.7, 119.9, 116.7, 116.0, 115.8, 62.5, 49.3. HRMS m/z calc. for $C_{19}H_{16}FN_3O_2 + H^+$: 338.1299; detected: 338.1294.

2-(4-(4-Formylphenyl)-1H-1,2,3-triazol-1-yl)ethyl cinnamate (8h)

Following general procedure IIA with azide **6** and 4-ethynylbenzaldehyde, compound **8h** was obtained as a white solid after silica gel circular chromatography (0 - 50% AcOEt/Hex), yield = 79%. Mp = 127 - 128 °C, $R_f = 0.39$ (50% AcOEt/Hex). ¹H NMR (400 MHz, CDCl₃, 25 °C), δ (ppm) = 10.05 (s, 1H, CHO), 8.05 (d, 2H, J = 8.1 Hz, H_{ar}), 7.98 (d, 2H, J = 8.1 Hz, H_{ar}), 7.73 (d, 1H, J = 16.0 Hz, =CHC_{ar}), 7.55 - 7.53 (m, 2H, H_{ar}), 7.45 - 7.39 (m, 3H, H_{ar}), 6.45 (d, 1H, J = 16.0 Hz, =CHCO), 4.81 (t, 2H, J = 5.1 Hz, OCH₂), 4.71 (t, 2H, J = 5.1 Hz, CH₂N); ¹³C NMR (101 MHz, CDCl₃, 25 °C), δ (ppm) = 166.3, 146.8, 146.4, 136.2, 135.9, 133.9, 130.8, 130.4, 129.0, 128.3, 126.1, 121.3, 116.6, 62.4, 49.5. HRMS m/z calc. for C₂₀H₁₇N₃O₃ : 348.1343; detected : 348.1339.

N-(2-(1H-1,2,3-Triazol-1-yl)ethyl)cinnamamide (9a)

Following general procedure I with azide **7,** compound **9a** was obtained as a beige powder after silica gel circular chromatography (0 – 1.5% MeOH/CH₂Cl₂), yield = 68%. Mp = 140 – 141 °C, R_f = 0.25 (7.5% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃, 25 °C), δ (ppm) = 7.70 (s, 1H, =CHN), 7.65 (d, 1H, J = 15.7 Hz, =CHC_{ar}), 7.61 (s, 1H, =CHN), 7.50 (m, 2H, H_{ar}), 7.37 (m, 3H, H_{ar}), 6.67 (br s, 1H, NH), 6.45 (d, 1H, J = 15.7 Hz, =CHCO), 4.63 (t, 2H, J = 5.7 Hz, CH₂-triazole), 3.95 (q, 2H, J = 5.7 Hz, NHCH₂). ¹³C NMR (101 MHz, CDCl₃, 25 °C), δ (ppm) = 166.51, 141.70, 134.56, 133.82, 129.92, 128.86, 127.89, 124.64, 120.00, 49.45, 39.58. HRMS m/z calc. for C₁₃H₁₄N₄O + (H⁺): 243.1240; detected: 243.1244.

N-(2-(4-Propyl-1H-1,2,3-triazol-1-yl)ethyl)cinnamamide. (9b)

Following general procedure IIA with azide **7** and 1-pentyne, compound **9b** was obtained as white crystals after silica gel circular chromatography (0 - 6% MeOH/CH₂Cl₂), yield = 39%. Mp = 156 - 157 °C, $R_f = 0.53$ (10% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃, 25 °C), δ (ppm) = 7.65 (d, 1H, J = 15.6 Hz, =CHC_{ar}), 7.54 - 7.49 (m, 2H, H_{ar}), 7.42 - 7.30 (m, 4H, H_{ar} + =CHN), 6.15 (br s, 1H, NH), 6.43 (d, 1H, J = 15.6 Hz, =CHCO), 4.54 (t, 2H, J = 5.6 Hz, CH₂-triazole), 3.94 (q, 2H, J = 5.6 Hz, CH₂NH), 2.69 (t, 2H, J = 7.6 Hz, CH₂CH₃), 1.65 - 1.75 (m, 2H,

CH₂CH₂CH₃), 0.98 (t, 2H, J = 7.4 Hz, CH₃); 13 C NMR (101 MHz, CDCl₃, 25 $^{\circ}$ C), δ (ppm) = 166.38, 141.63, 134.61, 129.87, 128.85, 127.87, 120.08, 49.38, 39.47, 27.62, 22.66, 13.78. HRMS m/z calc. for C₁₆H₂₀N₄O + H⁺: 285.1710; detected: 285.1702.

N-(2-(4-Cyclohexyl-1H-1,2,3-triazol-1-yl)ethyl)cinnamamide (**9c**)

Following general procedure IIA with azide **7** and ethynylcyclohexane, compound **9c** was obtained as white crystals after silica gel circular chromatography (0 - 4% MeOH/CH₂Cl₂), yield = 18%. Mp = 159 - 161 °C, R_f = 0.40 (6% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃, 25 °C), δ (ppm) = 7.65 (d, 1H, J = 15.6 Hz, =CHC_{ar}), 7.52 - 7.50 (m, 2H, H_{ar}), 7.41 - 7.37 (m, 4H, H_{ar} + =CHN), 6.69 (br s, 1H, NH), 6.46 (d, 1H, J = 15.6 Hz, =CHCO), 4.50 (t, 2H, J = 5.6 Hz, CH₂-triazole), 3.95 (q, 2H, J = 5.6 Hz, CH₂NH), 2.72 - 2.60 (m, 1H, CH-triazole), 1.81 - 1.71 (m, 4H, cyclohexyl), 1.38 - 1.42 (m, 4H, cyclohexyl), 1.27 - 1.24 (m, 2H, cyclohexyl); ¹³C NMR (101 MHz, CDCl₃, 25 °C), δ (ppm) = 166.43, 141.53, 134.65, 129.84, 128.84, 127.88, 120.23, 49.52, 39.42, 35.26, 32.92, 26.09, 25.98. HRMS m/z calc. for C₁₉H₂₄N₄O + H⁺: 325.2023; detected: 325.2014.

N-(2-(4-(Cyclohex-1-en-1-yl)-1H-1,2,3-triazol-1-yl)ethyl)cinnamamide (**9d**)

Following general procedure IIA with azide **7** and 1-ethynylcyclohex-1-ene, compound **9d** was obtained as a white solid after silica gel circular chromatography (0 - 4% MeOH/CH₂Cl₂), yield = 24%. Mp = 170 - 171 °C, $R_f = 0.44$ (6% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, acetone-d₆, 25 °C), δ (ppm) = 7.90 (s, 1H, =CHN), 7.59 – 7.52 (m, 4H, NH + =CHC_{ar} + H_{ar}), 7.42 – 7.36 (m, 3H, H_{ar}), 6.68 (d, 1H, J = 15.6 Hz, =CHCO), 6.48 - 6.45 (m, 1H, CH=C-triazole), 4.56 (t, 2H, J = 5.6 Hz, CH₂-triazole), 3.82 (q, 2H, J = 5.6 Hz, CH₂NH), 2.40 – 2.34 (m, 2H, cyclohexenyl), 2.20 – 2.14 (m, 2H, cyclohexenyl), 1.77 – 1.70 (m, 2H, cyclohexenyl), 1.70 – 1.61 (m, 2H, cyclohexenyl); ¹³C NMR (101 MHz, acetone-d₆, 25 °C), δ (ppm) = 165.49, 148.61, 139.73, 135.22, 129.43, 128.82, 127.93, 123.26, 121.51, 119.47, 49.14, 39.48, 25.98, 24.88, 22.34, 22.16. HRMS m/z calc. for C₁₉H₂₂N₄O + H⁺: 323.1866; detected: 323.1857.

N-(2-(4-Phenyl-1H-1,2,3-triazol-1-yl)ethyl)cinnamamide (**9e**)

Following general procedure IIA with azide **7** and ethynylbenzene, compound **9e** was obtained as a white solid after silica gel circular chromatography (0 - 7% MeOH/CH₂Cl₂), yield = 16%. Mp = 171 - 173 °C, $R_f = 0.40$ (36% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, DMSO-d₆, 25 °C), δ (ppm) = 8.60 (s, 1H, =CHN), 8.30 (m, 1H, NH), 7.87 - 7.84 (m, 2H, H_{ar}), 7.60 - 7.25 (m, 9H, =CHC_{ar} + H_{ar}), 6.60 (d, 1H, J = 15.6 Hz, =CHCO), 4.54 (t, 2H, J = 6.0 Hz, CH₂-triazole), 3.70 (q, 2H, J = 6.0 Hz, CH₂NH). ¹³C NMR (101 MHz, DMSO-d₆, 25 °C), δ (ppm) = 165.88, 146.75, 139.56, 135.20, 131.31, 130.01, 129.39, 129.35, 128.26, 128.03, 125.57, 122.17, 49.62, 39.45. HRMS m/z calc. for C₁₉H₁₈N₄O + H⁺: 319.1553; detected: 319.1553.

N-(2-(4-(p-Tolyl)-1H-1,2,3-triazol-1-yl)ethyl)cinnamamide (9f)

Following general procedure IIA with azide **7** and 1-ethynyl-4-methylbenzene, compound **9f** was obtained as a white solid after silica gel circular chromatography (0 - 3% MeOH/CH₂Cl₂), yield = 11%. Mp = 208 °C, R_f = 0.32 (6% MeOH/CH₂Cl₂). 1 H NMR (400 MHz, DMSO-d₆, 25 °C), δ (ppm) = 8.53 (s, 1H, =CHN), 8.33 (t, 1H, J = 5.7 Hz, NH), 7.73 (d, 2H, J = 8.0 Hz, H_{ar}), 7.60 – 7.30 (m, 6H, H_{ar} + =CHC_{ar}), 7.25 (d, 2H, J = 8.0 Hz, H_{ar}), 6.60 (d, 1H, J = 16.0 Hz, =CHCO), 4.52 (t, 2H, J = 5.7 Hz, CH₂-triazole), 3.69 (q, 2H, J = 5.7 Hz, CH₂NH), 2.32 (s, 3H, CH₃); 13 C NMR (101 MHz, DMSO-d₆, 25 °C), δ (ppm) = 165.86, 146.81, 139.54, 137.53, 135.20, 130.01, 129.90, 129.40, 128.54, 128.03, 125.51, 122.16, 121.74, 49.57, 39.45, 21.29. HRMS m/z calc. for C₂₀H₂₀N₄O + H⁺: 333.1710; detected: 333.1700.

N-(2-(4-(4-Fluorophenyl)-1H-1,2,3-triazol-1-yl)ethyl)cinnamamide (**9g**)

Following general procedure IIA with azide **7** and 1-ethynyl-4-fluorobenzene, compound **9g** was obtained as a white solid after silica gel circular chromatography (0 - 6% MeOH/CH₂Cl₂), yield = 41%. Mp = 193 - 196 °C, R_f = 0.52 (10% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, acetone-d₆, 25 °C), δ (ppm) = 8.39 (s, 1H, =CHN), 7.96 – 7.92 (m, 2H, H_{ar}), 7.60 – 7.55 (m, 4H, NH + =CHC_{ar} + H_{ar}), 7.43 – 7.37 (m, 3H, H_{ar}), 7.24 – 7.19 (m, 2H, H_{ar}), 6.68 (d, 1H, J = 16.0 Hz, =CHCO), 4.66 (t, 2H, J = 5.9 Hz, CH₂-triazole), 3.88 (q, 2H, J = 5.9 Hz, CH₂NH). ¹³C NMR (101 MHz,

acetone-d₆, 25 °C), δ (ppm) = 165.54, 163.55, 161.12, 146.01, 139.79, 135.20, 129.45, 128.83, 127.97, 127.93, 127.62, 127.25, 127.17, 121.46, 120.89, 115.64, 115.42, 49.46, 39.50. HRMS m/z calc. for $C_{19}H_{17}FN_4O + H^+$: 337.1459; detected: 337.1450.

N-(2-(4-(4-Formylphenyl)-1H-1,2,3-triazol-1-yl)ethyl)cinnamamide (9h)

Following general procedure IIA with azide **7** and 4-ethynylbenzaldehyde, compound **9h** was obtained as a white solid after silica gel circular chromatography (0 - 4% MeOH/CH₂Cl₂), yield = 21%. Mp = 200 - 201 °C, R_f = 0.42 (6% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, DMSO-d₆, 25 °C), δ (ppm) = 10.01 (s, 1H, CHO), 8.81 (s, 1H, =CHN), 8.35 (t, 1H, J = 5.6 Hz, NH), 8.08 (d, 2H, J = 8.0 Hz, H_{ar}), 7.79 (d, 2H, J = 8.0 Hz, H_{ar}), 7.60 – 7.30 (m, 6H, =CHC_{ar} + H_{ar}), 6.59 (d, 1H, J = 15.6 Hz, =CHCO), 4.57 (t, 2H, J = 5.7 Hz, CH₂-triazole), 3.71 (q, 2H, J = 5.6 Hz, CH₂NH). ¹³C NMR (101 MHz, DMSO-d₆, 25 °C), δ (ppm) = 192.98, 165.89, 145.67, 139.58, 136.93, 135.78, 135.18, 130.79, 130.02, 129.40, 128.03, 125.95, 123.81, 122.13, 49.81, 39.42. HRMS m/z calc. for C₂₀H₁₈N₄O₂ + H⁺: 347.1503; detected: 347.1497.

(E)-4-(3-(2-(1H-1,2,3-Triazol-1-yl)ethoxy)-3-oxoprop-1-en-1-yl)-1,2-phenylene diacetate (13a)

Following general procedure I with azide **11,** compound **13a** was obtained as a white powder after silica gel circular chromatography (1% MeOH/CH₂Cl₂), yield = 81%. Mp = 123 – 125 °C, R_f = 0.43 (4% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃, 25 °C), δ (ppm) = 7.76 (s, 1H, =CHN), 7.67 (s, 1H, =CHN), 7.63 (d, 1H, J = 16.0 Hz, CHC_{ar}), 7.42 (dd, 1H, J = 8.4 Hz, 1.9 Hz, H_{ar}), 7.38 (d, 1H, J = 1.8 Hz, H_{ar}), 7.25 (d, 1H, J = 8.3 Hz, H_{ar}), 6.36 (d, 1H, J = 16.0 Hz, =CHCO), 4.76 (t, 2H, J = 5.0 Hz, OCH₂), 4.64 (t, 2H, J = 5.2 Hz, CH₂N), 2.33 (s, 3H, CH₃COO), 2.32 (s, 3H, CH₃COO). ¹³C NMR (101 MHz, CDCl₃, 25 °C), δ (ppm) = 168.08, 167.96, 165.88, 144.23, 143.82, 142.50, 134.14, 132.81, 126.62, 124.04, 122.87, 117.93, 62.65, 48.99, 20.67, 20.63. HRMS m/z calc. for C₁₇H₁₇N₃O₆ + (H⁺) : 360.1190; detected : 360.1184.

(E)-4-(3-(2-(4-Cyclohexyl-1H-1,2,3-triazol-1-yl)ethoxy)-3-oxoprop-1-en-1-yl)-1,2-phenylene diacetate (13c)

Following general procedure IIB with azide **11** and ethynylcyclohexane, compound **13c** was obtained as a white solid after silica gel circular chromatography (0 – 2% MeOH/CH₂Cl₂), yield = 78%. Mp = 121 - 124 °C, $R_f = 0.31$ (2% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃, 25 °C), δ (ppm) = 7.64 (d, 1H, J = 16.0 Hz, =CHC_{ar}), 7.42 (dd, 1H, J = 8.4 Hz, 2.0 Hz, H_{ar}), 7.38 (d, 1H, J = 2.0 Hz, H_{ar}), 7.33 (s, 1H, =CHN), 7.26 (d, 1H, J = 8.4 Hz, H_{ar}), 6.38 (d, 1H, J = 16.0 Hz, =CHCO), 4.67 (t, 2H, J = 5.0 Hz, OCH₂), 4.61 (t, 2H, J = 5.0 Hz, CH₂N), 2.81 – 2.77 (m, 1H, CH-triazole), 2.33 (s, 3H, CH₃COO), 2.32 (s, 3H, CH₃COO), 2.09 – 2.04 (m, 2H, cyclohexyl), 1.87 – 1.81 (m, 4H, cyclohexyl), 1.49 – 1.36 (m, 4H, cyclohexyl); ¹³C NMR (101 MHz, CDCl₃, 25 °C), δ (ppm) = 168.1, 168.0, 165.9, 154.1, 144.1, 143.8, 142.5, 132.9, 126.6, 124.0, 122.9, 119.8, 118.1, 62.8, 53.4, 48.9, 35.3, 33.0, 26.1, 26.0, 20.7, 20.6. HRMS m/z calc. for C₂₃H₂₇N₃O₆ + H⁺: 442.1973; detected: 442.1964.

(E)-4-(3-(2-(4-(Cyclohex-1-en-1-yl)-1H-1,2,3-triazol-1-yl)ethoxy)-3-oxoprop-1-en-1-yl)-1,2-phenylene diacetate (13d)

Following general procedure IIB with azide **11** and 1-ethynyl-1-cyclohexene, compound **13d** was obtained as a white solid after silica gel circular chromatography (0 – 0.5% MeOH/CH₂Cl₂), yield = 67%. Mp = 118 - 120 °C, $R_f = 0.40$ (4% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃, 25 °C), δ (ppm) = 7.64 (d, 1H, J = 16.0 Hz, =CHC_{ar}), 7.48 (s, 1H, =CHN), 7.42 (dd, 1H, J = 8.4 Hz, 1.7 Hz, H_{ar}), 7.38 (d, 1H, J = 1.7 Hz, H_{ar}), 7.26 (d, 1H, J = 8.4 Hz, H_{ar}), 6.56 – 6.54 (m, 1H, CH=C-triazole), 6.37 (d, 1H, J = 16.0 Hz, =CHCO), 4.69 (t, 2H, J = 5.1 Hz, OCH₂), 4.62 (t, 2H, J = 5.1 Hz, NCH₂), 2.42 – 2.40 (m, 2H, cyclohexenyl), 2.34 (s, 3H, CH₃COO), 2.25 – 2.21 (m, 2H, cyclohexenyl), 1.82 – 1.76 (m, 2H, cyclohexenyl), 1.72 – 1.65 (m, 2H, cyclohexenyl); ¹³C NMR (101 MHz, CDCl₃, 25 °C), δ (ppm) = 168.08, 167.97, 165.95, 149.95, 144.15, 143.79, 142.49, 132.88, 127.15, 126.63, 125.35, 124.04, 122.86, 118.78, 118.06, 62.73, 49.02, 26.40, 25.27, 22.44, 22.19, 20.67, 20.63. HRMS m/z calc. for C₂₃H₂₅N₃O₆ + H⁺: 440.1816; detected: 440.1817.

(E)-4-(3-oxo-3-(2-(4-Phenyl-1H-1,2,3-triazol-1-yl)ethoxy)prop-1-en-1-yl)-1,2-phenylene diacetate (13e)

Following general procedure IIB with azide **11** and ethynylbenzene, compound **13e** was obtained as a white solid after silica gel circular chromatography (0 – 40% AcOEt/Hex), yield = 46%. Mp = 158 - 160 °C, $R_f = 0.41$ (60% AcOEt/Hex). ¹H NMR (400 MHz, CDCl₃, 25 °C), δ (ppm) = 7.88 – 7.85 (m, 3H, H_{ar} + =CHN), 7.65 (d, 1H, J = 16.0 Hz, =CHC_{ar}), 7.47 – 7.34 (m, 5H, H_{ar}), 7.24 (d, 1H, J = 8.4, H_{ar}), 6.38 (d, 1H, J = 16.0 Hz, =CHCO), 4.76 (t, 2H, J = 5.0 Hz, OCH₂), 4.68 (t, 2H, J = 5.0 Hz, CH₂N), 2.33 (s, 3 H, CH₃COO). 2.32 (s, 3 H, CH₃COO); ¹³C NMR (101 MHz, CDCl₃, 25 °C), δ (ppm) = 168.1, 168.0, 165.9, 148.1, 144.3, 143.8, 142.5, 132.8, 130.4, 128.9, 128.3, 126.7, 125.8, 124.0, 122.9, 120.2, 118.0, 62.7, 49.3, 20.7, 20.6. HRMS m/z calc. for $C_{23}H_{21}N_3O_6 + H^+$: 436.1503; detected: 436.1499.

(E)-4-(3-oxo-3-(2-(4-(p-Tolyl)-1H-1,2,3-triazol-1-yl)ethoxy)prop-1-en-1-yl)-1,2-phenylene diacetate (13f)

Following general procedure IIB with azide **11** and 1-ethynyl-4-methylebenzene, compound **13f** was obtained as a white solid after silica gel circular chromatography (0.4% MeOH/CH₂Cl₂), yield = 78%. Mp = 156 - 158 °C, $R_f = 0.47$ (3% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃, 25 °C), δ (ppm) = 7.82 (s, 1H, =CHN), 7.75 (d, 2H, J = 8.0 Hz, H_{ar}), 7.65 (d, 1H, J = 16.0 Hz, =CHC_{ar}), 7.41 (dd, 1H, J = 8.4 Hz; 1.7 Hz, H_{ar}), 7.37 (d, 1H, J = 1.8 Hz, H_{ar}), 7.28-7.23 (m, 3H, H_{ar}), 6.38 (d, 1H, J = 16.0 Hz, =CHCO), 4.75 (t, 2H, J = 5.0 Hz, OCH₂), 4.67 (t, 2H, J = 5.0 Hz, CH₂N), 2.34 (s, 3H, CH₃C_{ar}), 2.33 (s, 3H, CH₃COO), 2.32 (s, 3H, CH₃COO). ¹³C NMR (101 MHz, CDCl₃, 25 °C), δ (ppm) = 168.07, 167.95, 165.95, 148.18, 144.74, 143.81, 142.49, 138.13, 132.84, 129.56, 127.61, 126.66, 125.70, 124.02, 122.87, 119.81, 117.99, 62.68, 49.21, 21.30, 20.67, 20.62. HRMS m/z calc. for C₂₄H₂₃N₃O₆ + H⁺: 450.1660; detected: 450.1660.

(E)-4-(3-(2-(4-(4-Fluorophenyl)-1H-1,2,3-triazol-1-yl)ethoxy)-3-oxoprop-1-en-1-yl)-1,2-phenylene diacetate (13g)

Following general procedure IIB with azide 11 and 1-ethynyl-4-fluorobenzene, compound 13g was obtained as a white solid after silica gel circular chromatography (0 - 1% MeOH/CH₂Cl₂),

yield = 93%. Mp = 138 °C, R_f = 0.41 (2% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃, 25 °C), δ (ppm) = 7.85 – 7.82 (m, 3H, H_{ar} + =CHN), 7.65 (d, 1H, J = 16.0 Hz, =CHC_{ar}), 7.41 (dd, 1H, J = 8.4 Hz, J = 1.8 Hz, J = 1.9 H

(E)-4-(3-(2-(4-(4-Formylphenyl)-1H-1,2,3-triazol-1-yl)ethoxy)-3-oxoprop-1-en-1-yl)-1,2-phenylene diacetate (13h)

Following general procedure IIB with azide **11** and 4-ethynylbenzaldehyde, compound **13h** was obtained as a white solid after silica gel circular chromatography (0 - 1% MeOH/CH₂Cl₂), yield = 82%. Mp = 149 - 150 °C, $R_f = 0.31$ (2% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃, 25 °C), δ (ppm) = 10.04 (s, 1H, CHO), 8.04 (d, 2H, J = 8.4 Hz, H_{ar}), 7.99 – 7.95 (m, 3 H, H_{ar} + =CHN), 7.64 (d, 1H, J = 16.0 Hz, =CHC_{ar}), 7.42 – 7.46 (m, 2H, H_{ar}), 7.24 (dd, 1 H, J = 8,4 Hz, J = 1,8 Hz, H_{ar}), 6.38 (d, 1H, J = 15.9 Hz, =CHCO), 4.79 (t, 2H, J = 4.9 Hz, OCH₂), 4.70 (t, 2H, J = 4.9 Hz, CH₂N), 2.33 (s, 3H, CH₃COO), 2.32 (s, 3H, CH₃COO); ¹³C NMR (101 MHz, CDCl₃, 25 °C), δ (ppm) = 191.7, 168.1, 168.0, 165.9, 146.8, 144.4, 144.4, 143.9, 142.5, 136.2, 135.9, 132.7, 130.4, 126.6, 126.1, 124.1, 122.9, 121.4, 121.4, 117.8, 62.5, 49.4, 20.7, 20.6. HRMS m/z calc. for C₂₄H₂₁N₃O₇ + H⁺: 464.1452; detected: 464.1447.

(E)-4-(3-((2-(1H-1,2,3-Triazol-1-yl)ethyl)amino)-3-oxoprop-1-en-1-yl)-1,2-phenylene diacetate (14a)

Following general procedure I with azide **12,** compound **14a** was obtained as a white powder after silica gel circular chromatography (0.5 – 2% MeOH/CH₂Cl₂), yield = 76%. Mp = 174 – 176 °C, $R_f = 0.30$ (5% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃, 25 °C), δ (ppm) = 7.70 (s, 1H, =CHN), 7.60 (s, 1H, =CHN), 7.56 (d, 1H, J = 15.7 Hz, =CHC_{ar}), 7.35 (m, 2H, H_{ar}), 7.20 (d, 1H, J

= 8.5 Hz, H_{ar}), 6.70 (br s, 1H, NH), 6.36 (d, 1H, J = 15.7 Hz, =CHCO), 4.60 (t, 2H, J = 5.7 Hz, CH₂-triazole), 3.91 (q, 2H, J = 5.7 Hz, NHC**H**₂), 2.32 (s, 3H, CH₃), 2.31 (s, 3H, CH₃). ¹³C NMR (101 MHz, CDCl₃, 25 °C), δ (ppm) = 168.18, 168.14, 166.03, 143.09, 142.36, 139.73, 133.58, 126.30, 124.65, 123.86, 12243, 121.27, 49.36, 39.58, 20.67, 20.64. HRMS m/z calc. for C₁₇H₁₈N₄O₅ + (H⁺) : 359.1350; detected : 359.1347.

(E)-4-(3-oxo-3-((2-(4-Propyl-1H-1,2,3-triazol-1-yl)ethyl)amino)prop-1-en-1-yl)-1,2-phenylene diacetate (**14b**)

Following general procedure IIB with azide **12** and 1-pentyne, compound **14b** was obtained as a white solid after silica gel circular chromatography (0.5 – 1.5% MeOH/CH₂Cl₂), yield = 62%. Mp = 134 – 136 °C, $R_f = 0.58$ (7.5% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃, 25 °C), δ (ppm) = 7.60 (d, 1H, J = 15.7 Hz, =CHC_{ar}), 7.37 (dd, 1H, J = 8.4 Hz, 1.7 Hz, H_{ar}), 7.33 (d, 1H, J = 1.7 Hz, H_{ar}), 7.31 (s, 1H, =CHN), 7.21 (d, 1H, J = 8.4 Hz, H_{ar}), 6.61 (br s, 1H, NH), 6.36 (d, 1H, J = 15.7 Hz, =CHCO), 4.52 (t, 2H, J = 5.9 Hz, CH₂-triazole), 3.91 (q, 2H, J = 5.9 Hz, NHC**H**₂), 2.69 (t, 2H, J = 7.6 Hz, C**H**₂CH₂CH₃), 2.32 (s, 3H, CH₃COO), 2.31 (s, 3H, CH₃COO), 1.70 (m, 2H, CH₂CH₂CH₃), 0.97 (t, 3H, J = 7.3 Hz, CH₃). ¹³C NMR (101 MHz, CDCl₃, 25 °C), δ (ppm) = 168.12, 168.08, 165.91, 148.33, 143.11, 142.37, 139.73, 133.60, 126.25, 123.85, 122.45, 121.82, 121.29, 49.29, 39.50, 27.60, 22.66, 20.66, 20.62, 13.77. HRMS m/z calc. for $C_{20}H_{24}N_4O_5 + (H^+) : 401.1819$; detected : 401.1826

(E)-4-(3-((2-(4-Cyclohexyl-1H-1,2,3-triazol-1-yl)ethyl)amino)-3-oxoprop-1-en-1-yl)-1,2-phenylene diacetate (<math>14c)

Following general procedure IIB with azide **12** and ethynylcyclohexane, compound **14c** was obtained as a white solid after silica gel circular chromatography (0 – 1.1% MeOH/CH₂Cl₂), yield = 61%. Mp = 141 – 144 °C, R_f = 0.45 (5% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃, 25 °C), δ (ppm) = 7.58 (d, 1H, J = 15.7 Hz, =CHC_{ar}), 7.38 (dd, 1H, J = 8.4 Hz, 1.7 Hz, H_{ar}), 7.33 (d, 1H, J = 1.6 Hz, H_{ar}), 7.28 (s, 1H, =CHN), 7.21 (d, 1H, J = 8.4 Hz, H_{ar}), 6.63 (br s, 1H, NH),

6.37 (d, 1H, J = 15.7 Hz, =CHCO), 4.52 (t, 2H, J = 5.9 Hz, CH₂-triazole), 3.91 (q, 2H, J = 5.9 Hz, NHC**H**₂), 2.74 (m, 1H, CH-triazole), 2.32 (s, 3H, CH₃COO), 2.31 (s, 3H, CH₃COO), 2.05 (m, 2H, cyclohexyl), 1.82-1.72 (m, 2H, cyclohexyl), 1.45-1.24 (m, 6H, cyclohexyl). 13 C NMR (101 MHz, CDCl₃, 25 °C), δ (ppm) = 168.13, 168.09, 165.91, 153.78, 143.10, 142.37, 139.70, 133.62, 126.24, 123.86, 122.46, 121.33, 120.54, 49.33, 39.47, 35.21, 32.98, 26.09, 25.98, 20.67, 20.62. HRMS m/z calc. for C₂₃H₂₈N₄O₅ + (H⁺): 441.2132; detected: 441.2126.

(E)-4-(3-((2-(4-(Cyclohex-1-en-1-yl)-1H-1,2,3-triazol-1-yl)ethyl)amino)-3-oxoprop-1-en-1-yl)-1,2-phenylene diacetate (**14d**)

Following general procedure IIB with azide **12** and 1-ethynylcyclohex-1-ène, compound **14d** was obtained as a white solid after silica gel circular chromatography (0 – 1% MeOH/CH₂Cl₂), yield = 70%. Mp = 160 – 162 °C, $R_f = 0.28$ (5% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃, 25 °C), δ (ppm) = 7.57 (d, 1H, J = 15.7 Hz, =CHC_{ar}), 7.42 (s, 1H, =CHN), 7.37 (d, 1H, J = 8.4 Hz, H_{ar}), 7.33 (s, 1H, H_{ar}), 7.20 (d, 1H, J = 8.4 Hz, H_{ar}), 6.69 (br s, 1H, NH), 6.48 (m, 1H, CH=C-triazole), 6.37 (d, 1H, J = 15.7 Hz, =CHCO), 4.53 (t, 2H, J = 5.4 Hz, CH₂-triazole), 3.92 (q, 2H, J = 5.4 Hz, NHCH₂), 2.36 (m, 2H, cyclohexenyl), 2.32 (s, 3H, CH₃COO), 2.31 (s, 3H, CH₃COO), 2.19 (m, 2H, cyclohexenyl), 1.78-1.66 (m, 4H, cyclohexenyl). ¹³C NMR (101 MHz, CDCl₃, 25 °C), δ (ppm) = 168.12, 168.09, 165.97, 149.48, 143.10, 142.36, 139.68, 133.62, 127.05, 126.24, 125.35, 123.85, 122.47, 121.34, 119.49, 49.45, 39.59, 26.34, 25.26, 22.40, 22.14, 20.67, 20.62. HRMS m/z calc. for C₂₃H₂₆N₄O₅ + (H⁺): 439.1976; detected: 439.1976

(E)-4-(3-oxo-3-((2-(4-Phenyl-1H-1,2,3-triazol-1-yl)ethyl)amino)prop-1-en-1-yl)-1,2-phenylene diacetate (**14e**)

Following general procedure IIB with azide **12** and ethynylbenzene, compound **14e** was obtained as a white solid after silica gel circular chromatography (0 – 1% MeOH/CH₂Cl₂), yield = 28%. Mp = 142 – 148 °C, R_f = 0.38 (5% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃, 25 °C), δ (ppm) = 7.77 – 7.74 (m, 3H, H_{ar} + =CHN), 7.57 (d, 1H, J = 15.7 Hz, =CHC_{ar}), 7.41 – 7.30 (m, 5H, H_{ar}), 7.17 (d, 1H, J = 8.4 Hz, H_{ar}), 6.86 (br s, 1H, NH), 6.39 (d, 1H, J = 15.7 Hz, =CHCO), 4.60 (m,

2H, CH₂-triazole), 3.94 (m, 2H, C**H**₂NH), 2.30 (s, 3H, CH₃CO), 2.29 (s, 3H, CH₃CO). ¹³C NMR (101 MHz, CDCl₃, 25 °C), δ (ppm) = 168.13, 168.10, 166.11, 147.73, 143.09, 142.33, 139.76, 133.57, 130.16, 128.91, 128.34, 126.28, 125.63, 123.83, 122.47, 121.30, 120.81, 49.67, 39.66, 20.66, 20.60. HRMS m/z calc. For. C₂₃H₂₂N₄O₅ + (H⁺): 435.1663; detected: 435.1660.

(E)-4-(3-oxo-3-((2-(4-(p-Tolyl)-1H-1,2,3-triazol-1-yl)ethyl)amino)prop-1-en-1-yl)-1,2-phenylene diacetate (**14f**)

Following general procedure IIB with azide **12** and 1-ethynyl-4-methylbenzene, compound **14f** was obtained as a white solid after silica gel circular chromatography (0 – 1.4% MeOH/CH₂Cl₂), yield = 61%. Mp = 177 – 178 °C, R_f = 0.48 (AcOEt). ¹H NMR (400 MHz, CDCl₃, 25 °C), δ (ppm) = 7.71 (s, 1H, =CHN), 7.62 (d, 2H, J = 8.0 Hz, H_{ar}), 7.57 (d, 1H, J = 15.7 Hz, =CHC), 7.34 - 7.29 (m, 2H, H_{ar}), 7.20 - 7.15 (m, 3H, H_{ar}), 6.95 (br s, 1H, NH), 6.40 (d, 1H, J = 15.7 Hz, =CHCO), 4.58 (t, 2H, J = 5.4 Hz, CH₂-triazole), 3.92 (q, 2H, J = 5.4 Hz, NHCH₂), 2.37 (s, 3H, CH₃Ph), 2.30 (s, 3H, CH₃COO), 2.29 (s, 3H, CH₃COO). ¹³C NMR (101 MHz, CDCl₃, 25 °C), δ (ppm) = 168.13, 168.10, 166.11, 147.79, 143.06, 142.32, 139.65, 138.21, 133.62, 129.56, 127.33, 126.26, 125.52, 123.81, 122.48, 121.39, 120.48, 49.62, 39.66, 21.27, 20.66, 20.59. HRMS m/z calc. for C₂₄H₂₄N₄O₅ + (H⁺): 449.1819; detected: 449.1820.

(E)-4-(3-((2-(4-(4-Fluorophenyl)-1H-1,2,3-triazol-1-yl)ethyl)amino)-3-oxoprop-1-en-1-yl)-1,2-phenylene diacetate (**14g**)

Following general procedure IIB with azide **12** and 1-ethynyl-4-methylbenzene, compound **14g** was obtained as a white solid after silica gel circular chromatography (0 – 1.3% MeOH/CH₂Cl₂), yield = 58%. Mp = 165 °C, $R_f = 0.50$ (5% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃, 25 °C), δ (ppm) = 7.79-7.75 (m, 3H, =CHN + H_{ar}), 7.59 (d, 1H, J = 15.7 Hz, =CHC_{ar}), 7.36 (dd, 1H, J = 8.4 Hz, 2.0 Hz, H_{ar}), 7.32 (d, 1H, J = 2.0 Hz, H_{ar}), 7.20 (d, 1H, J = 8.4 Hz, H_{ar}), 7.15 - 7.10 (m, 2H, H_{ar}), 6.39 (t, 1H, J = 5.7 Hz, NH), 6.34 (d, 1H, J = 15.7 Hz, =CHCO), 4.62 (t, 2H, J = 5.7 Hz, CH₂-triazole), 3.98 (q, 2H, J = 5.7 Hz, NHC**H**₂), 2.32 (s, 3H, CH₃COO), 2.31 (s, 3H, CH₃COO). ¹³C NMR (101 MHz, CDCl₃, 25 °C), δ (ppm) = 168.11, 168.05, 165.92, 163.99, 161.52,

147.03, 143.20, 142.39, 140.07, 133.44, 127.47, 127.39, 126.47, 126.44, 126.28, 123.89, 122.46, 120.99, 120.47, 116.03, 115.82, 49.64, 39.58, 20.65, 20.61. HRMS m/z calc. for $C_{23}H_{21}FN_4O_5 + (H^+)$: 453.1569; detected: 453.1567.

(E)-4-(3-((2-(4-(4-Formylphenyl)-1H-1,2,3-triazol-1-yl)ethyl)amino)-3-oxoprop-1-en-1-yl)-1,2-phenylene diacetate (**14h**)

Following general procedure IIB with azide **12** and 1-ethynyl-4-methylbenzene, compound **14h** was obtained as a white solid after silica gel circular chromatography (0 – 1.3% MeOH/CH₂Cl₂), yield = 51%. Mp = 181 – 182 °C, R_f = 0.33 (5% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, DMSOd₆, 25 °C), δ (ppm) = 10.02 (s, 1H, CHO), 8.81 (s, 1H, =CHN), 8.35 (t, 1H, J = 5.7 Hz, NH), 8.10 (d, 2H, J = 8.2 Hz, H_{ar}), 7.99 (d, 2H, J = 8.2 Hz, H_{ar}), 7.51-7.48 (m, 2H, H_{ar}), 7.43 (d, 1H, J = 15.7 Hz, =CHC_{ar}), 7.31 (d, 1H, J = 8.1 Hz, H_{ar}), 6.58 (d, 1H, J = 15.7 Hz, =CHCO), 4.58 (t, 2H, J = 5.7 Hz, CH₂-triazole), 3.71 (q, 2H, J = 5.7 Hz, NHC**H**₂), 2.30 (s, 3H, CH₃COO), 2.29 (s, 3H, CH₃COO). ¹³C NMR (101 MHz, DMSO-d₆, 25 °C), δ (ppm) = 192.99, 168.66, 168.62, 165.63, 145.67, 143.21, 142.75, 137.93, 136.93, 135.78, 134.09, 130.80, 126.43, 125.96, 124.61, 123.82, 123.23, 122.82, 49.78, 39.29, 20.82, 20.81. HRMS m/z calc. for C₂₄H₂₂N₄O₆ + (H⁺): 463.1612; detected: 463.1619.

(*E*)-2-(*4-Propyl-1H-1*,2,*3-triazol-1-yl*)*ethyl 3-*(*3*,*4-dihydroxyphenyl*)*acrylate* (*15b*)

Following general procedure III with acetylated caffeoyl derivative **13b**, compound **15b** was obtained as a white powder, yield = 43%. Mp = 180 – 181 °C (dec.), $R_f = 0.41$ (5% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, DMSO-d₆, 25 °C), δ (ppm) = 9.66 (br s, 1H, OH), 9.24 (br s, 1H, OH), 7.92 (s, 1H =CHN), 7.44 (d, 1H, J = 15.9 Hz, =CHC_{ar}), 7.03 (s, 1H, H_{ar}), 6.99 (d, 1H, J = 8.3 Hz, H_{ar}), 6.76 (d, 1H, J = 8.3 Hz, H_{ar}), 6.22 (d, 1H, J = 15.9 Hz, =CHCO), 4.64 (t, 2H, J = 5.0 Hz, OCH₂), 4.49 (t, 2H, J = 5.0 Hz, CH₂N), 2.59 (t, 2H, J = 7.5 Hz, **CH**₂CH₂CH₃), 1.60 (sext., 2H, J = 7.4 Hz, CH₂CH₂CH₃), 0.88 (t, 3H, J = 7.4 Hz, CH₃). ¹³C NMR (101 MHz, DMSO-d₆, 25 °C), δ (ppm) = 166.57, 149.03, 147.24, 146.20, 146.04, 125.81, 122.78, 121.95,

116.18, 115.36, 113.73, 62.75, 48.90, 27.48, 22.72, 14.01. HRMS m/z calc. for $C_{16}H_{19}N_3O_4 + (H^+)$: 318.1448; detected: 318.1455.

(*E*)-2-(4-*Cyclohexyl-1H-1,2,3-triazol-1-yl*)ethyl 3-(3,4-dihydroxyphenyl)acrylate (**15c**)

Following general procedure III with acetylated caffeoyl derivative **13c**, compound **15c** was obtained as a white powder, yield = 80%. Mp = 191 °C (dec.), R_f = 0.33 (5% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, DMSO-d₆, 25 °C), δ (ppm) = 9.65 (br s, 1H, OH), 9.15 (br s, 1H, OH), 7.90 (s, 1H, =CHN), 7.44 (d, 1H, J = 15.9 Hz, =CHC_{ar}), 7.04 (s, 1H, H_{ar}), 6.99 (d, 1H, J = 8.2 Hz, H_{ar}), 6.76 (d, 1H, J = 8.2 Hz, H_{ar}), 6.23 (d, 1H, J = 15.9 Hz, =CHCO), 4.63 (t, 2H, J = 4.8 Hz, OCH₂), 4.48 (t, 2H, J = 4.8 Hz, CH₂N), 2.70 – 2.61 (m, 1H, CH-triazole), 2.33 (s, 3H, CH₃COO), 2.32 (s, 3H, CH₃COO), 1.98 – 1.88 (m, 2H, cyclohexyl), 1.76 – 1.62 (m, 4H, cyclohexyl), 1.41 – 1.30 (m, 4H, cyclohexyl); ¹³C NMR (101 MHz, DMSO-d₆, 25 °C), δ (ppm) = 166.56, 152.64, 149.03, 146.21, 146.04, 125.82, 121.95, 121.54, 116.18, 115.37, 113.75, 62.72, 48.90, 35.01, 33.02, 26.08, 25.99. HRMS m/z calc. for C₁₉H₂₃N₃O₄ + (H⁺): 358.1761; detected: 358.1760.

(E)-2-(4-(Cyclohex-1-en-1-yl)-1H-1,2,3-triazol-1-yl)ethyl 3-(3,4-dihydroxyphenyl)acrylate (15d)

Following general procedure III with acetylated caffeoyl derivative **13d**, compound **15d** was obtained as a white powder, yield = 75%. Mp = 219 - 220 °C (dec.), $R_f = 0.35$ (5% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, DMSO-d₆, 25 °C), δ (ppm) = 9.65 (br s, 1H, OH), 9.16 (br s, 1H, OH), 8.15 (s, 1H, =CHN), 7.45 (d, 1H, J = 15.9 Hz, =CHC_{ar}), 7.04 (d, 1H, J = 1.8 Hz, H_{ar}), 7.00 (dd, 1H, J = 8.2 Hz, 1.8 Hz, H_{ar}), 6.76 (d, 1H, J = 8.2 Hz, H_{ar}), 6.40 - 6.38 (m, 1H, CH=C-triazole), 6.23 (d, 1H, J = 15.9 Hz, =CHCO), 2.32 - 2.38 (m, 2H, cyclohexenyl), 2.15 - 2.13 (m, 2H, cyclohexenyl), 1.72 - 1.66 (m, 2H, cyclohexenyl), 1.63 - 1.59 (m, 2H, cyclohexenyl), 1.72 - 1.66 (m, 2H, cyclohexenyl), 1.63 - 1.59 (m, 2H, cyclohexenyl), 1.25.81, 123.87, 121.97, 120.78, 116.18, 115.38, 113.72, 62.70, 49.06, 26.26, 25.11, 22.48, 22.33. HRMS m/z calc. for C₁₉H₂₁N₃O₄ + (H⁺): 356.1605; detected: 356.1611.

(*E*)-2-(4-*Phenyl-1H-1,2,3-triazol-1-yl*)ethyl 3-(3,4-dihydroxyphenyl)acrylate (**15e**)

Following general procedure III with acetylated caffeoyl derivative **13e,** compound **15e** was obtained as a light brown powder, yield = 51%. Mp = 193 - 195 °C (dec.), $R_f = 0.32$ (5% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, DMSO-d₆, 25 °C), δ (ppm) = 9.65 (br s, 1H, OH), 9.17 (br s, 1H, OH), 8.68 (s, 1H, =CHN), 7.67 (d, 2H, J = 7.4 Hz, H_{ar}), 7.49-7.43 (m, 3H, H_{ar} + =CHC_{ar}), 7.34 (m, 1H, H_{ar}), 7.05 (s, 1H, H_{ar}), 6.99 (d, 1H, J = 8.2 Hz, H_{ar}), 6.76 (d, 1H, J = 8.2 Hz, H_{ar}), 6.25 (d, 1H, J = 15.9 Hz, =CHCO), 4.62 (t, 2H, J = 4.7 Hz, OCH₂), 4.57 (t, 2H, J = 4.7 Hz, CH₂N). ¹³C NMR (101 MHz, DMSO-d₆, 25 °C), δ (ppm) = 166.64, 149.04, 146.87, 146.30, 146.04, 131.19, 129.38, 128.34, 125.81, 125.61, 122.34, 121.99, 116.19, 115.40, 113.70, 62.67, 49.36. HRMS m/z calc. for C₁₉H₁₇N₃O₄ + (H⁺): 352.1292; detected: 352.1302.

(*E*)-2-(4-(*p*-*Tolyl*)-1*H*-1,2,3-triazol-1-yl)ethyl 3-(3,4-dihydroxyphenyl)acrylate (**15f**)

Following general procedure III with acetylated caffeoyl derivative **13f**, compound **15f** was obtained as a white powder, yield = 79%. Mp = 181 - 182 °C (dec.), $R_f = 0.26$ (5% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, DMSO-d₆, 25 °C), δ (ppm) = 9.64 (br s, 1H, OH), 9.156 (br s, 1H, OH), 8.60 (s, 1H, =CHN), 7.74 (d, 2H, J = 8.0 Hz, H_{ar}), 7.47 (d, 1H, J = 15.9 Hz, =CHC_{ar}), 7.26 (d, 2H, J = 8.0 Hz, H_{ar}), 7.04 (s, 1H, H_{ar}), 6.99 (d, 1H, J = 8.2 Hz, H_{ar}), 6.75 (d, 1H, J = 8.2 Hz, H_{ar}), 6.25 (d, 1H, J = 15.9 Hz, =CHCO), 4.74 (t, 2H, J = 4.7 Hz, OCH₂), 4.56 (t, 2H, J = 4.7 Hz, CH₂N), 2.33 (s, 3H, C_{ar}-CH₃). ¹³C NMR (101 MHz, DMSO-d₆, 25 °C), δ (ppm) = 166.64, 149.03, 146.94, 146.29, 146.03, 137.63, 129.92, 128.42, 125.82, 125.55, 122.00, 121.89, 116.17, 115.38, 113.72, 62.67, 49.31, 21.30. HRMS m/z calc. for C₂₀H₁₉N₃O₄ + (H⁺): 366.1448; detected: 366.1454.

(*E*)-2-(4-(4-*Fluorophenyl*)-1*H*-1,2,3-*triazol*-1-*yl*)*ethyl* 3-(3,4-*dihydroxyphenyl*)*acrylate* (**15g**)

Following general procedure III with acetylated caffeoyl derivative **13g** compound **15g** was obtained as a white powder, yield = 63%. Mp = 238 - 240 °C (dec.), $R_f = 0.28$ (5% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, DMSO-d₆, 25 °C), δ (ppm) = 9.65 (br s, 1H, OH), 9.15 (br s, 1H, OH), 8.66 (s, 1H, =CHN), 7.90 (t, 2H, J = 8.6 Hz, H_{ar}), 7.47 (d, 1H, J = 15.9 Hz, =CHC_{ar}),

7.29 (d, 2H, J = 8.6 Hz, H_{ar}), 7.04 (s, 1H, H_{ar}), 6.99 (d, 1H, J = 8.2 Hz, H_{ar}), 6.75 (d, 1H, J = 8.2 Hz, H_{ar}), 6.25 (d, 1H, J = 16.0 Hz, =CHCO), 4.75 (t, 2H, J = 4.6 Hz, OCH₂), 4.56 (t, 2H, J = 4.6 Hz, CH₂N), ¹³C NMR (101 MHz, DMSO-d₆, 25 °C), δ (ppm) = 166.64, 163.44, 161.01, 149.04, 146.29, 146.03, 127.75, 127.67, 127.58, 125.82, 122.23, 122.00, 116.42, 116.20, 116.17, 115.39, 113.71, 62.65, 49.39. HRMS m/z calc. for $C_{19}H_{16}FN_3O_4 + (H^+)$: 370.1198; detected: 370.1201.

(*E*)-2-(4-(4-*Formylphenyl*)-1*H*-1,2,3-*triazol*-1-*yl*)*ethyl* 3-(3,4-*dihydroxyphenyl*)*acrylate* (*15h*)

Following general procedure III with acetylated caffeoyl derivative **13h,** compound **15h** was obtained as a beige powder, yield = 61%. Mp = 220 - 230 °C (dec.), $R_f = 0.32$ (5% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, DMSO-d₆, 25 °C), δ (ppm) = 10.019 (s, 1H, CHO), 9.65 (br s, 1H, OH), 9.15 (br s, 1H, OH), 8.88 (s, 1H, =CHN), 8.10 (d, 2H, J = 8.2 Hz, H_{ar}), 8.00 (d, 2H, J = 8.2 Hz, H_{ar}), 7.47 (d, 1H, J = 15.8 Hz, =CHC_{ar}), 7.04 (s, 1H, H_{ar}), 6.99 (d, 1H, J = 8.2 Hz, H_{ar}), 6.75 (d, 1H, J = 8.2 Hz, H_{ar}), 6.23 (d, 1H, J = 15.9 Hz, =CHCO), 4.79 (t, 2H, J = 4.7 Hz, OCH₂), 4.58 (t, 2H, J = 4.7 Hz, CH₂N), ¹³C NMR (101 MHz, DMSO-d₆, 25 °C), δ (ppm) = 192.99, 166.63, 149.04, 146.32, 146.03, 145.79, 136.79, 135.84, 130.80, 126.01, 125.81, 123.94, 122.00, 116.17, 115.39, 113.69, 62.60, 49.54. HRMS m/z calc. for C₂₀H₁₇N₃O₅ + (H⁺): 380.1241; detected: 380.1250.

(*E*)-*N*-(2-(1*H*-1,2,3-*Triazol*-1-y*l*)ethy*l*)-3-(3,4-dihydroxypheny*l*)acrylamide (**16a**)

Following general procedure III with acetylated caffeoyl derivative **14a**, compound **16a** was obtained as a white powder, yield = 54%. Mp = 163 - 165 °C, $R_f = 0.15$ (7.5% MeOH/CH₂Cl₂).

¹H NMR (400 MHz, DMSO-d₆, 25 °C), δ (ppm) = 9.41 (br s, 1H, OH), 9.16 (br s, 1H, OH), 8.19 (br s, 1H, NH), 8.12 (s, 1H, =CHN), 7.72 (s, 1H, =CHN), 7.24 (d, 1H, J = 15.7 Hz, =CHC_{ar}), 6.94 (s, 1H, H_{ar}), 6.83 (d, 1H, J = 8.1 Hz, H_{ar}), 6.75 (d, 1H, J = 8.1 Hz, H_{ar}), 6.28 (d, 1H, J = 15.7 Hz, =CHCO), 4.50 (t, 2H, J = 5.9 Hz, CH-triazole), 3.61 (q, 2H, J = 5.9 Hz, NHCH₂).

¹³C NMR (101 MHz, DMSO-d₆, 25 °C), δ (ppm) = 166.27, 147.88, 146.00, 140.02, 133.67, 126.65, 125.51, 120.95, 118.37, 116.22, 114.32, 49.17, 39.36. HRMS m/z calc. for $C_{13}H_{14}N_4O_3 + (H^+)$: 275.1139; detected : 274.1146

(*E*)-3-(3,4-Dihydroxyphenyl)-*N*-(2-(4-propyl-1H-1,2,3-triazol-1-yl)ethyl)acrylamide (*16b*)

Following general procedure III with acetylated caffeoyl derivative **14b**, compound **16b** was obtained as a grey solide, yield = 55%. Mp = 163 – 165 °C, $R_f = 0.33\%$ (7.5% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, MeOD, 25 °C), δ (ppm) = 7.73 (s, 1H, =CHN), 7.39 (d, 1H, J = 15.7 Hz, =CHC_{ar}), 7.00 (d, 1H, J = 1.7 Hz, H_{ar}), 6.90 (dd, 1H, J = 8.4 Hz, 1.8 Hz, H_{ar}), 6.77 (d, 1H, J = 8.4 Hz, H_{ar}), 6.31 (d, 1H, J = 15.7 Hz, CHCO), 4.56 (t, 2H, J = 5.9 Hz, CH₂-triazole), 3.77 (t, 2H, J = 5.9 Hz, CH₂NH), 2.68 (t, 2H, J = 7.6 Hz, CH₂CH₂CH₃), 1.69 (m, 2H, CH₂CH₂CH₃), 0.97 (t, 3H, J = 7.4 Hz, CH₃). ¹³C NMR (101 MHz, MeOD, 25 °C), δ (ppm) =168.19, 149.67, 147.52, 145.34, 141.36, 126.70, 122.23, 120.79, 116.37, 115.03, 113.62, 49.02, 39.25, 26.87, 22.35, 12.55. HRMS m/z calc. for C₁₆H₂₀N₄O₃ + (H⁺) : 317.1608; detected : 317.1612.

(E)-N-(2-(4-Cyclohexyl-1H-1,2,3-triazol-1-yl)ethyl)-3-(3,4-dihydroxyphenyl)acrylamide (16c)

Following general procedure III with acetylated caffeoyl derivative **14c**, compound **16c** was obtained as a beige solide, yield = 81%. Mp = 183 - 184, $R_f = 0.42\%$ (7.5% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, DMSO-d₆, 25 °C), δ (ppm) = 9.39 (br s, 1H, OH), 9.14 (br s, 1H, OH), 8.16 (m, 1H, NH), 7.81 (s, 1H, =CHN), 7.24 (d, 1H, J = 15.7 Hz, =CHC_{ar}), 6.93 (d, 1H, J = 1.9 Hz, H_{ar}), 6.83 (dd, 1H, J = 8.2 Hz, 1.9 Hz, H_{ar}), 6.74 (d, 1H, J = 8.2 Hz, H_{ar}), 6.29 (d, 1H, J = 15.7 Hz, =CHCO), 4.41 (t, 2H, J = 6.0 Hz, CH₂-triazole), 3.59 (q, 2H, J = 6.0 Hz, NHCH₂), 2.63 (m, 1H, CH-triazole), 1.98 - 1.91 (m, 2H, cyclohexyl), 1.73 - 1.67 (m, 2H, cyclohexyl), 1.41 - 1.19 (m, 6H, cyclohexyl). ¹³C NMR (101 MHz, DMSO-d₆, 25 °C), δ (ppm) = 166.28, 152.45, 147.86, 145.99, 140.00, 126.68, 121.31, 120.96, 118.41, 116.19, 114.28, 49.15, 39.47, 35.05, 33.00, 26.11, 26.01. HRMS m/z calc. for C₁₉H₂₄N₄O₃ + (H⁺): 357.1912; detected : 357.1930.

(E)-N-(2-(4-(Cyclohex-1-en-1-yl)-1H-1,2,3-triazol-1-yl)ethyl)-3-(3,4-dihydroxyphenyl)acrylamide (**16d**)

Following general procedure III with acetylated caffeoyl derivative **14d**, compound **16d** was obtained as a beige solide, yield = 80%. Mp = 168 – 169 °C, $R_f = 0.40\%$ (7.5% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, MeOD, 25 °C), δ (ppm) = 7.90 (s, 1H, =CHN), 7.39 (d, 1H, J = 15.7 Hz,

=CHC_{ar}), 7.00 (s, 1H, H_{ar}), 6.91 (d, 1H, J = 8.0 Hz, H_{ar}), 6.77 (d, 1H, J = 8.0 Hz, H_{ar}), 6.44 (br s, 1H, CH=C-triazole), 6.31 (d, 1H, J = 15.7 Hz, =CHCO), 4.56 (t, 2H, J = 5.5 Hz, CH₂-triazole), 3.77 (t, 2H, J = 5.5 Hz, NHCH₂), 2.38 (m, 2H, cyclohexenyl), 2.31 (m, 2H, cyclohexenyl), 1.78 (m, 2H, cyclohexenyl), 1.69 (m, 2H, cyclohexenyl). ¹³C NMR (101 MHz, MeOD, 25 °C), δ (ppm) = 168.24, 149.10, 147.52, 145.33, 141.38, 127.01, 126.71, 124.63, 120.82, 119.92, 116.38, 115.03, 113.63, 49.14, 39.26, 25.91, 24.82, 22.16, 21.87. HRMS m/z calc. for $C_{19}H_{22}N_4O_3 + (H^+)$: 355.1765; detected : 355.1772

(*E*)-3-(3,4-Dihydroxyphenyl)-*N*-(2-(4-phenyl-1H-1,2,3-triazol-1-yl)ethyl)acrylamide (**16e**)

Following general procedure III with acetylated caffeoyl derivative **14e**, compound **16e** was obtained as a beige solide, yield = 73%. Mp = 208 °C (dec.), R_f = 0.40% (10% MeOH/CH₂Cl₂). 1 H NMR (400 MHz, DMSO-d₆, 25 °C), δ (ppm) = 9.39 (br s, 1H, OH), 9.14 (br s, 1H, OH), 8.59 (s, 1H, =CHN), 8.21 (br s, 1H, NH), 7.84 (m, 2H, H_{ar}), 7.43 (m, 2H, H_{ar}), 7.31 (m, 1H, H_{ar}), 7.25 (d, 1H, J = 15.7 Hz, =CHC_{ar}), 6.93 (s, 1H, H_{ar}), 6.83 (d, 1H, J = 7.3 Hz, H_{ar}), 6.73 (d, 1H, J = 7.3 Hz, H_{ar}), 6.29 (d, 1H, J = 15.7 Hz, =CHCO), 4.52 (m, 2H, CH₂-triazole), 3.68 (m, 2H, NHCH₂). 13 C NMR (101 MHz, DMSO-d₆, 25 °C), δ (ppm) = 166.34, 147.88, 146.73, 145.99, 140.07, 131.31, 129.36, 128.26, 126.65, 125.57, 122.18, 120.97, 118.37, 116.19, 114.31, 49.69, 39.29. HRMS m/z calc. for C₁₉H₁₈N₄O₃ + (H⁺) : 351.1452; detected : 351.1447.

(E)-3-(3,4-Dihydroxyphenyl)-N-(2-(4-(p-tolyl)-1H-1,2,3-triazol-1-yl)ethyl)acrylamide (**16f**)

Following general procedure III with acetylated caffeoyl derivative **14f**, compound **16f** was obtained as a beige solide, yield = 66%. Mp = 220 °C (dec.), R_f = 0.34% (7.5% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, DMSO-d₆, 25 °C), δ (ppm) = 9.39 (s, 1H, OH), 9.13 (s, 1H, OH), 8.52 (s, 1H, =CHN), 8.21 (t, 1H, J = 5.7 Hz, NH), 7.73 (d, 2H, J = 8.0 Hz, H_{ar}), 7.27-7.23 (m, 3H, H_{ar} + =CHC_{ar}), 6.93 (d, 1H, J = 1.6 Hz, H_{ar}), 6.83 (dd, 1H, J = 8.2 Hz, 1.6 Hz, H_{ar}), 6.73 (d, 1H, J = 8.2 Hz, H_{ar}), 6.29 (d, 1H, J = 15.7 Hz, =CHCO), 4.51 (t, 2H, J = 5.7 Hz, CH₂-triazole), 3.66 (q, 2H, J = 5.7 Hz, NHC**H**₂), 2.33 (s, 3H, CH₃). ¹³C NMR (101 MHz, DMSO-d₆, 25 °C), δ (ppm) = 166.33, 147.87, 146.79, 145.98, 140.06, 137.52, 129.90, 128.55, 126.66, 125.52, 121.74, 120.96,

118.39, 116.20, 114.32, 49.64, 39.32, 21.30. HRMS m/z calc. for $C_{20}H_{20}N_4O_3 + (H^+)$: 365.1608; detected: 365.1614.

(E)-3-(3,4-Dihydroxyphenyl)-N-(2-(4-(4-fluorophenyl)-1H-1,2,3-triazol-1-yl)ethyl)acrylamide (16g)

Following general procedure III with acetylated caffeoyl derivative **14g**, compound **16g** was obtained as a light yellow solid, yield = 68%. Mp = 226 °C (dec.), $R_f = 0.36\%$ (7.5% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, DMSO-d₆, 25 °C), δ (ppm) = 9.39 (s, 1H, OH), 9.13 (s, 1H, OH), 8.58 (s, 1H, =CHN), 8.20 (m, 1H, NH), 7.88 (m, 2H, H_{ar}), 7.31-7.23 (m, 3H, H_{ar} + =CHC_{ar}), 6.93 (d, 1H, J = 1.8 Hz, H_{ar}), 6.83 (dd, 1H, J = 8.2 Hz, 1.8 Hz, H_{ar}), 6.74 (d, 1H, J = 8.2 Hz, H_{ar}), 6.28 (d, 1H, J = 15.7 Hz, =CHCO), 4.52 (t, 2H, J = 5.7 Hz, CH₂-triazole), 3.66 (q, 2H, J = 5.7 Hz, NHC**H**₂). ¹³C NMR (101 MHz, DMSO-d₆, 25 °C), δ (ppm) = 166.34, 163.39, 160.96, 147.88, 145.99, 145.88, 140.07, 127.90, 127.61, 127.53, 126.65, 122.10, 120.98, 118.36, 116.41, 116.19, 114.30, 49.72, 39.36. HRMS m/z calc. for C₁₉H₁₇FN₄O₃ + (H⁺): 369.1357; detected: 369.1362.

(E)-3-(3,4-Dihydroxyphenyl)-N-(2-(4-(4-formylphenyl)-1H-1,2,3-triazol-1-yl)ethyl)acrylamide (16h)

Following general procedure III with acetylated caffeoyl derivative **14h**, compound **16h** was obtained as a white solid, yield = 58%. Mp = 228 – 230 °C (dec.), R_f = 0.20% (5% MeOH/CH₂Cl₂). ¹H NMR (400 MHz, DMSO-d₆, 25 °C), δ (ppm) = 10.02 (s, 1H, CHO), 9.40 (br s, 1H, OH), 9.14 (br s, 1H, OH), 8.80 (s, 1H, =CHN), 8.21 (t, 1H, J = 5.7 Hz, NH), 8.09 (d, 2H, J = 8.2 Hz, H_{ar}), 7.99 (d, 2H, J = 8.2 Hz, H_{ar}), 7.25 (d, 1H, J = 15.7 Hz, =CHC_{ar}), 6.93 (s, 1H, H_{ar}), 6.83 (d, 1H, J = 8.1 Hz, H_{ar}), 6.73 (d, 1H, J = 8.1 Hz, H_{ar}), 6.28 (d, 1H, J = 15.7 Hz, =CHCO), 4.55 (t, 2H, J = 5.7 Hz, CH₂-triazole), 3.69 (q, 2H, J = 5.7 Hz, NHC**H**₂). ¹³C NMR (101 MHz, DMSO-d₆, 25 °C), δ (ppm) = 193.00, 163.35, 147.89, 145.99, 145.65, 140.09, 136.94, 135.78, 130.80, 126.64, 125.96, 123.82, 120.98, 118.35, 116.20, 114.31, 49.89, 39.47. HRMS m/z calc. for C₂₀H₁₈N₄O₄ + (H⁺): 379.1401; detected: 379.1405.